Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Marcoumar, Marcumar
Synonyms :
phenprocoumon
Class :
Anticoagulants
Brand Name :
Marcoumar, Marcumar
Synonyms :
phenprocoumon
Class :
Anticoagulants
Dosage forms and strengths Â
Film-coated tabletÂ
1.5 mgÂ
3 mg Â
Oral tabletÂ
3 mgÂ
According to Invivo’s data
Day first single dosage- The recommended dose is to take 12 mg to 15 mg orally
Day second single dosage- The recommended dose is to take 6 mg to 9 mg orally
The treatment regimen proceeds with ongoing administration of reduced doses, usually in the range of 1.5 mg to 6 mg a day, given as a maintenance dosage
Not indicatedÂ
Refer adult dosingÂ
obinutuzumab: they may increase the hypotensive effect of Blood Pressure Lowering Agents
amifostine: they may increase the hypotensive effect when combined with blood viscosity reducing agents
clozapine: they may increase the hypotensive effect of blood viscosity reducing agents
quinidine: they may increase the hypotensive effect of blood viscosity reducing agents
pentamycin increases the therapeutic effectiveness of phenprocoumon when used in combination
bromeperidol: they may decrease the hypotensive effect of blood viscosity reducing agents
cabergoline: they may increase the hypotensive effect of blood viscosity reducing agents
eluxadoline: they may increase the hypotensive effect of blood viscosity reducing agents
oxomemazine: they may increase the hypotensive effect of blood viscosity reducing agents
oxatomide: they may increase the hypotensive effect of blood viscosity reducing agents
potassium chloride: they may increase the hypotensive effect of blood viscosity reducing agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
blood viscosity-reducing agents: they may increase the hypotensive effect when combined with hypotension-associated agents
maitake: they may increase the hypoglycemic effect of blood glucose lowering effects
pegvisomant: they may increase the hypoglycemic effect of Agents with blood viscosity reducing agents
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
quinolones: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
choline magnesium trisalicylate
salicylates: they may increase the hypoglycemic effect of agents with blood viscosity reducing agents
alfuzosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
arginine: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
benperidol: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
brimonidine: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
diazoxide: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
duloxetine: may enhance the hypotensive effect when combined with blood viscosity-reducing agents
naftopidil: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
nicorandil: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
nitroprusside: may increase the hypotensive effect when combined with blood viscosity-lowering agents
pentoxifylline: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
pholcodine: they may increase the hypotensive effect when combined with blood viscosity-lowering agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
prostacyclin analogues: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
silodosin: they may increase the hypotensive effect when combined with blood viscosity-reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
Phosphodiesterase 5 Inhibitors: they may increase the hypotensive effect when combined with blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
monoamine oxidase inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
prothionamide: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
selective serotonin reuptake inhibitors (A2): they may increase the hypoglycemic effect of blood viscosity reducing agents
barbiturates: they may increase the hypotensive effect of blood viscosity reducing agents
quinagolide: they may increase the hypotensive effect of blood viscosity reducing agents
molsidomine: they may increase the hypotensive effect of blood viscosity reducing agents
relugolix/​estradiol/​norethindrone
androgens: they may increase the hypoglycemic effect of blood viscosity reducing agents
relugolix/estradiol/norethindrone
androgens: they may increase the hypoglycemic effect of blood viscosity reducing agents
androgens: they may increase the hypoglycemic effect of blood viscosity reducing agents
androgens: they may increase the hypoglycemic effect of blood viscosity reducing agents
androgens: they may increase the hypoglycemic effect of blood viscosity reducing agents
Monoamine Oxidase Inhibitors: they may increase the hypoglycemic effect of blood viscosity reducing agents
aripiprazole lauroxil: they may increase the hypotensive effect of blood viscosity reducing agents
cimetidine: they may increase the hypotensive effect of blood viscosity reducing agents
ispaghula husk may lower or decrease the rate of GI absorption of coumarin derivatives
Actions and Spectrum:Â
Action:
phenprocoumon is a vitamin K antagonist, which means it inhibits the action of vitamin K in the body. Vitamin K is essential for synthesizing specific proteins, including blood clotting factors. By inhibiting the action of vitamin K, phenprocoumon reduces the production of these clotting factors, leading to an increased time for the blood to clot. This aids in the prevention of blood clot formation which can be dangerous when they block blood vessels and potentially lead to conditions like deep vein thrombosis (DVT), pulmonary embolism, or stroke.Â
Spectrum:Â
Deep Vein Thrombosis (DVT): phenprocoumon can be prescribed to individuals at risk of developing DVT, that is development of blood clots within the deep veins, most commonly occurring in the lower extremities. It can prevent the clot from growing larger and reduce the risk of embolism.Â
Atrial Fibrillation: In individuals with atrial fibrillation (an irregular heartbeat), there is an increased risk of blood clots forming in the heart. phenprocoumon can help reduce this risk and prevent the formation of clots that could lead to stroke.Â
Frequency not defined Â
Bleeding gumsÂ
NosebleedsÂ
blood in urineÂ
Hematomas after injuriesÂ
Black Box Warning:Â Â
None
Contraindication/Caution:Â Â
Hypersensitivity: Individuals with a known hypersensitivity or allergy to phenprocoumon or its components should not use this medication.Â
Active Bleeding: phenprocoumon should not be used in patients with active bleeding disorders, such as gastrointestinal bleeding, intracranial bleeding, or other significant hemorrhagic events.Â
Severe Hepatic Impairment: Patients with severe liver impairment or liver disease should avoid phenprocoumon, as the liver metabolizes it, and impaired liver function can affect its clearance from the body.Â
Severe Renal Impairment: While phenprocoumon is primarily metabolized in the liver, individuals with severe kidney impairment should be cautious when using this medication, as impaired renal function can indirectly affect its metabolism.Â
Vitamin K Deficiency: phenprocoumon works by inhibiting the action of vitamin K, which is necessary for the synthesis of clotting factors. Patients with severe vitamin K deficiency should not use this medication.Â
Pregnancy and Breastfeeding: phenprocoumon is commonly not recommended for use during pregnancy because of its association with potential birth defects and bleeding complications. It is also contraindicated in nursing womens.Â
Â
Pregnancy warnings:    Â
Pregnancy category: N/AÂ
Lactation: Excreted into human milk is unknownÂ
Pregnancy Categories:        Â
Category A: Studies that were well-controlled and met expectations revealed no risk to the fetus in either the first or second trimester.Â
Category B: There were a lack of studies on pregnant women and no evidence of risk to the fetus in animal experiments.  Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.   Â
Category D: adequate data with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.  Â
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.   Â
Category N: There is no data available for the drug under this category
Pharmacology: phenprocoumon is an anticoagulant medication in the class of vitamin K antagonists.Â
Pharmacodynamics:Â Â
phenprocoumon works by inhibiting the action of vitamin K, an essential cofactor in producing several blood-clotting factors in the liver. Specifically, it interferes with the regeneration of vitamin K, which is necessary for the carboxylation of clotting factors II, VII, IX, and X. This results in the synthesis of undercarboxylated and less functional clotting factors, leading to an anticoagulant effect.Â
Pharmacokinetics:Â
AbsorptionÂ
phenprocoumon is well-absorbed when taken orally, with a slow onset of action. Peak plasma concentrations are typically reached within 4-6 hours after ingestion.Â
DistributionÂ
It binds extensively to plasma proteins, primarily albumin. It has a relatively large volume of distribution, indicating that it can distribute into various tissues throughout the body.Â
MetabolismÂ
phenprocoumon undergoes hepatic metabolism. Cytochrome P450 enzymes, particularly CYP2C9, play a significant role in metabolism.Â
Excretion and EliminationÂ
It is eliminated in the urine and feces, with a half-life ranging from several days to a few weeks. The long half-life contributes to its sustained anticoagulant effect.Â
Administration: Â
The dosage of phenprocoumon varies from person to person and depends on the specific medical condition it is being used to treat. Â
The physician will establish the suitable dosage for every patient according to their specific requirements.Â
Patient information leafletÂ
Generic Name: phenprocoumonÂ
Why do we use phenprocoumon? Â
phenprocoumon is used to prevent and treat DVT, which occurs when blood clots form in the deep veins of the legs. People who have atrial fibrillation, a condition characterized by an irregular heart rhythm, face a heightened risk of stroke because of the potential development of blood clots within the heart. phenprocoumon is used to prevent these clots from forming and causing a stroke.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
